Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Idiopathic Subglottic Stenosis

Interventions

DRUG

Taltz

Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks

Trial Locations (1)

RECRUITING

Yale New Haven Hospital, New Haven